🇺🇸 FDA
Pipeline program

Tagraxofusp

STML-401-0423

Phase 2 small_molecule active

Quick answer

Tagraxofusp for Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Stemline Therapeutics B.V.
Indication
Acute Myeloid Leukemia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials